Adamas Pharmaceuticals, Inc. ADMS
$ 8.22
0.0%
Adamas Pharmaceuticals, Inc. Income Statement 2011-2024 | ADMS
Annual Income Statement Adamas Pharmaceuticals, Inc.
2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
164 M | 141 M | 239 M | 886 M | 323 M | 310 M | 250 M | - | - | - |
Shares |
27.7 M | 27.7 M | 26.9 M | 22.6 M | 21.7 M | 18.1 M | 14.8 M | - | - | - |
Net Income |
-57.4 M | -105 M | -131 M | -89.5 M | -60.1 M | -51.8 M | 10.2 M | 50.9 M | 17.7 M | - |
Revenue |
74.5 M | 54.6 M | 34 M | 571 K | 572 K | 1.92 M | 55.8 M | 71.1 M | 37.5 M | - |
EBITDA |
-43.3 M | -91 M | -114 M | -86.7 M | -60.2 M | -57 M | 18.7 M | 57.1 M | 20 M | - |
Operating Expenses |
117 M | 144 M | 148 M | 88.5 M | 61.6 M | 59.4 M | 37.3 M | 14.1 M | 17.5 M | - |
General and Administrative Expenses |
107 M | 114 M | 109 M | 61.3 M | 30.3 M | 23.5 M | 15.5 M | 6.67 M | 8.33 M | - |
All numbers in USD currency